On November 05, 2015 Calithera Biosciences, Inc. (Nasdaq:CALA), reported that four abstracts highlighting the potential of CB-839, the Company’s novel, orally bioavailable glutaminase inhibitor for the treatment of hematological malignancies, have been selected for presentation at the 57th American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting and exposition, taking place December 5-8, 2015, in Orlando, Florida (Press release, Calithera Biosciences, NOV 5, 2015, View Source;p=RssLanding&cat=news&id=2107378 [SID:1234508338]). Details for the presentations are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Metabolomic, Proteomic and Genomic Profiling Identifies Biomarkers of Sensitivity to Glutaminase
Abstract #1802
Andrew L. MacKinnon, Ph.D., Calithera Biosciences
Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
Saturday, December 5, 2015 at 5:30-7:30 PM ET
Orange County Convention Center, Hall A

Role of Glutamine in Metabolic and Epigenetic Reprogramming in AML
Abstract #2559
Juliana Velez Lujan, Ph.D., University of Texas MD Anderson Cancer Center
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Sunday, December 6, 2015 at 6:00-8:00 PM ET
Orange County Convention Center, Hall A

Phase I Study of CB-839, a First-in-class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients With Relapsed/ Refractory Leukemia
Abstract #2566
Eunice S. Wang, M.D., Roswell Park Cancer Institute
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Sunday, December 6, 2015 at 6:00-8:00 PM ET
Orange County Convention Center, Hall A

Phase I Study of CB-839, a First-in-class, Glutaminase Inhibitor in Patients With Multiple Myeloma and Lymphoma
Abstract #3059
Dan Vogl, M.D., University of Pennsylvania
Session Name: 653. Myeloma: Therapy, excluding Transplantation: Poster II
Sunday, December 6, 2015 at 6:00-8:00 PM ET
Orange County Convention Center, Hall A

The meeting abstracts can be viewed online through the ASH (Free ASH Whitepaper) website at www.hematology.org.